References
Schmid M, Frick JS, Malek N, Goetz M (2017) Successful treatment of pouchitis with vedolizumab, but not fecal microbiota transfer (FMT), after proctocolectomy in ulcerative colitis. Int J Color Dis 32(4):597–598
Shen B (2012) Acute and chronic pouchitis—pathogenesis, diagnosis and treatment. Nat Rev Gastroenterol Hepatol 9(6):323–333
Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A; GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369(8):699–710
Philpott J, Ashburn J, Shen B (2017) Efficacy of vedolizumab in patients with antibiotic and anti-tumor necrosis alpha refractory pouchitis. Inflamm Bowel Dis 23(1):E5–E6
Acknowledgements
None.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Financial support
None.
Competing interests
The authors declare that they have no competing interests.
Informed consent
Patient consent and IRB approval were obtained.
Rights and permissions
About this article
Cite this article
Mir, F., Yousef, M.H., Partyka, E.K. et al. Successful treatment of chronic refractory pouchitis with vedolizumab. Int J Colorectal Dis 32, 1517–1518 (2017). https://doi.org/10.1007/s00384-017-2854-0
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00384-017-2854-0